Science

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

Piet Ost/X

Jan 19, 2025, 07:56

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

Piet Ost, Radiation Oncologist Iridium Network Antwerp, shared a post on X about a recent abstract by him and colleagues, presented at 2025 ASCO Genitourinary Cancers Symposium:

“Does SBRT for oligorecurrent prostate cancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO.

Presented by Chad Tang at GU25.”

“World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.”

Authors: Chad Tang, Alexander Sherry, Hyunsoo Hwang, David Palma, Piet Ost et al.

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

2025 ASCO Genitourinary Cancers Symposium Alexander Sherry cancer Chad Tang David Palma GU25 Hyunsoo Hwang OncoDaily Oncology Piet Ost prostate cancer WOLVERINE

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer